Associate Professor Howard Gurney

Clinical Associate Professor
Medicine, Westmead Clinical School

Telephone 02 9845 6954
Fax 02 98456391

Map

Selected grants

2013

  • Building multidisciplinary research linkages - the University of Sydney and Chulalongkorn University Symposium; Meyer W, Dietz H, Freckelton L, George J, Gurney H, Hyett J, Snowdon J, Napathorn S, Chaisamran U, Chindamporn A, Srikiatkhachorn A; DVC International/IPDF Grant.

2012

  • A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study); Gurney H, Balleine R, Wilcken N, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Response to Chemotherapy in Ovarian Cancer; deFazio A, Gurney H, Chenevix-Trench G, Haber M, Gurney H, Harnett P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2009

  • Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients; Murray M, Gurney H, McLachlan A; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Diekstra, M., Klumpen, H., Lolkema, M., Yu, H., Kloth, J., Gelderblom, H., Van Schaik, R., Gurney, H., Swen, J., Huitema, A., et al (2014). Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clinical Pharmacology and Therapeutics, 96(1), 81-89. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., B, L., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Zhou, F., Zheng, J., Zhu, L., Jodal, A., Cui, P., Wong, K., Gurney, H., Church, W., Murray, M. (2013). Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. The AAPS Journal, 15(4), 1099-1108. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]
  • Parente, P., Parnis, F., Gurney, H. (2012). Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective. Asia-Pacific Journal of Clinical Oncology, 8(1), 31-42. [More Information]
  • Gao, B., Yeap, S., Clements, A., Balakrishnar, B., WONG, M., Gurney, H. (2012). Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 30(32), 4017-4025. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Eechoute, K., Franke, R., Loos, W., Scherkenbach, L., Boere, I., Verweij, J., Gurney, H., Kim, R., Tirona, R., Mathijssen, R., et al (2011). Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 89(6), 816-820. [More Information]
  • Clements, A., Gao, B., Yeap, S., Wong, K., Ali, S., Gurney, H. (2011). Metformin in prostate cancer: two for the price of one. Annals of Oncology, 22(12), 2556-2560. [More Information]
  • Klumpen, J., Samer, C., Mathijssen, R., Schellens, J., Gurney, H. (2011). Moving Towards Dose Individualization of Tyrosine Kinase Inhibitors. Cancer Treatment Reviews, 37(4), 251-260. [More Information]
  • Nguyen, V., Gurney, H., van der Poorten, D. (2011). Paraneoplastic Hepatic Dysfunction in Metastatic Prostate Cancer: The Role of Cytokine Dysregulation. Journal of Clinical Oncology, 29(2), e21-e23. [More Information]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Klumpen, J., Beijnen, J., Gurney, H., Schellens, J. (2010). Inhibitors of mTOR. The Oncologist, 15(12), 1262-1269. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
  • Mathijssen, R., Gurney, H. (2009). Irinogenetics: how many stars are there in the sky? Journal of Clinical Oncology, 27(16), 2578-2579. [More Information]
  • Gao, B., Klumpen, H., Gurney, H. (2008). Dose calculation of anticancer drugs. Expert opinion on drug metabolism & toxicology, 4(10), 1307-1319. [More Information]
  • Lin, C., Turner, S., Gurney, H., Peduto, A. (2008). Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? Journal of Medical Imaging and Radiation Oncology, 52(4), 376-381. [More Information]
  • Bell, D., Grimes, D., Gurney, H., Dalley, D., Blackwell, T., Fox, R., Jeffery, M. (2008). Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Internal Medicine Journal, 38(10), 751-757. [More Information]
  • Klumpen, H., Liddle, C., Gurney, H. (2008). Transporter pumps and imatinib: A cause of pharmacokinetic resistance? Cancer Biology & Therapy, 7(3), 416-418. [More Information]
  • Goodwin, A., Gurney, H., Gottlieb, D. (2007). Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effect. Internal Medicine Journal, 37(2), 127-129. [More Information]
  • Rosenthal, M., Woo, H., Gurney, H., Copeman, M., Yellin, O. (2007). Death of a clinical trial: a speculative inclusion criterion gone wrong. Internal Medicine Journal, 37(12), 838-839. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Gurney, H., Dear, R. (2007). Obesity in dose calculation: a mouse or an elephant? Journal of Clinical Oncology, 25(30), 4703-4704. [More Information]
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]
  • Spry, N., Kristjanson, L., Hooton, B., Hayden, L., Neerhut, G., Gurney, H., Corica, T., Korbel, E., Weinstein, S., McCaul, K. (2006). Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. European Journal of Cancer, 42(8), 1083-1092. [More Information]
  • Gurney, H. (2006). Developing a New Framework for Dose Calculation. Journal of Clinical Oncology, 24(10), 1489-1490.
  • Holmes-Walker, J., Woo, H., Gurney, H., Do, V., Chipps, D. (2006). Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 184(4), 176-179. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., et al (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455.
  • van Ufford-Mannesse, P., Spry, N., Byth Wilson, K., Berry, M., Hayden, L., Korbel, E., Woo, H., Gurney, H. (2005). Changes of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancer. Journal of Clinical Oncology, 23(16S (June 1 Supplement)), 418S-418S.
  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Pharmacology and Therapeutics, 77(1). [More Information]
  • Gurney, H. (2005). I don't underdose my patients..do I? Lancet Oncology, 6(9), 637-638. [More Information]
  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]
  • Gurney, H., Shannon, C., Crombie, C., Brooks, A., Lau,, H., Drummond, M. (2001). Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Annals of Oncology, 12, 947-952.
  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • King, M., Hall, J., Caleo, S., Gurney, H., Harnett, P. (2000). Home or Hospital? An evaluation of the costs, preferences and outcomes of domiciliary chemotherapy. International Journal of Health Services, 30(3), 557-579.

2014

  • Diekstra, M., Klumpen, H., Lolkema, M., Yu, H., Kloth, J., Gelderblom, H., Van Schaik, R., Gurney, H., Swen, J., Huitema, A., et al (2014). Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clinical Pharmacology and Therapeutics, 96(1), 81-89. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., B, L., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]

2013

  • Zhou, F., Zheng, J., Zhu, L., Jodal, A., Cui, P., Wong, K., Gurney, H., Church, W., Murray, M. (2013). Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. The AAPS Journal, 15(4), 1099-1108. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Won, A., Gurney, H., Marx, G., de Souza, P., Patel, M. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU International, 112(4), E250-E255. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]

2012

  • Parente, P., Parnis, F., Gurney, H. (2012). Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective. Asia-Pacific Journal of Clinical Oncology, 8(1), 31-42. [More Information]
  • Gao, B., Yeap, S., Clements, A., Balakrishnar, B., WONG, M., Gurney, H. (2012). Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 30(32), 4017-4025. [More Information]

2011

  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Eechoute, K., Franke, R., Loos, W., Scherkenbach, L., Boere, I., Verweij, J., Gurney, H., Kim, R., Tirona, R., Mathijssen, R., et al (2011). Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 89(6), 816-820. [More Information]
  • Clements, A., Gao, B., Yeap, S., Wong, K., Ali, S., Gurney, H. (2011). Metformin in prostate cancer: two for the price of one. Annals of Oncology, 22(12), 2556-2560. [More Information]
  • Klumpen, J., Samer, C., Mathijssen, R., Schellens, J., Gurney, H. (2011). Moving Towards Dose Individualization of Tyrosine Kinase Inhibitors. Cancer Treatment Reviews, 37(4), 251-260. [More Information]
  • Nguyen, V., Gurney, H., van der Poorten, D. (2011). Paraneoplastic Hepatic Dysfunction in Metastatic Prostate Cancer: The Role of Cytokine Dysregulation. Journal of Clinical Oncology, 29(2), e21-e23. [More Information]

2010

  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Boland, A., Simes, R., et al (2010). Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. National Cancer Institute. Journal, 102(16), 1253-1262. [More Information]
  • Klumpen, J., Beijnen, J., Gurney, H., Schellens, J. (2010). Inhibitors of mTOR. The Oncologist, 15(12), 1262-1269. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]

2009

  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Soloman, B., Toner, G. (2009). An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology, 32(4), 338-341. [More Information]
  • Mathijssen, R., Gurney, H. (2009). Irinogenetics: how many stars are there in the sky? Journal of Clinical Oncology, 27(16), 2578-2579. [More Information]

2008

  • Gao, B., Klumpen, H., Gurney, H. (2008). Dose calculation of anticancer drugs. Expert opinion on drug metabolism & toxicology, 4(10), 1307-1319. [More Information]
  • Lin, C., Turner, S., Gurney, H., Peduto, A. (2008). Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? Journal of Medical Imaging and Radiation Oncology, 52(4), 376-381. [More Information]
  • Bell, D., Grimes, D., Gurney, H., Dalley, D., Blackwell, T., Fox, R., Jeffery, M. (2008). Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Internal Medicine Journal, 38(10), 751-757. [More Information]
  • Klumpen, H., Liddle, C., Gurney, H. (2008). Transporter pumps and imatinib: A cause of pharmacokinetic resistance? Cancer Biology & Therapy, 7(3), 416-418. [More Information]

2007

  • Goodwin, A., Gurney, H., Gottlieb, D. (2007). Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effect. Internal Medicine Journal, 37(2), 127-129. [More Information]
  • Rosenthal, M., Woo, H., Gurney, H., Copeman, M., Yellin, O. (2007). Death of a clinical trial: a speculative inclusion criterion gone wrong. Internal Medicine Journal, 37(12), 838-839. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Gurney, H., Dear, R. (2007). Obesity in dose calculation: a mouse or an elephant? Journal of Clinical Oncology, 25(30), 4703-4704. [More Information]
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]

2006

  • Spry, N., Kristjanson, L., Hooton, B., Hayden, L., Neerhut, G., Gurney, H., Corica, T., Korbel, E., Weinstein, S., McCaul, K. (2006). Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. European Journal of Cancer, 42(8), 1083-1092. [More Information]
  • Gurney, H. (2006). Developing a New Framework for Dose Calculation. Journal of Clinical Oncology, 24(10), 1489-1490.
  • Holmes-Walker, J., Woo, H., Gurney, H., Do, V., Chipps, D. (2006). Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 184(4), 176-179. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., et al (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455.

2005

  • van Ufford-Mannesse, P., Spry, N., Byth Wilson, K., Berry, M., Hayden, L., Korbel, E., Woo, H., Gurney, H. (2005). Changes of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancer. Journal of Clinical Oncology, 23(16S (June 1 Supplement)), 418S-418S.
  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Pharmacology and Therapeutics, 77(1). [More Information]
  • Gurney, H. (2005). I don't underdose my patients..do I? Lancet Oncology, 6(9), 637-638. [More Information]

2004

  • Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. Pharmacology and Therapeutics, 75(6), 529-538. [More Information]

2001

  • Gurney, H., Shannon, C., Crombie, C., Brooks, A., Lau,, H., Drummond, M. (2001). Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Annals of Oncology, 12, 947-952.

2000

  • Rischin, D., Smith, J., Millward, M., Lewis, C., Richardson, G., Boyer, M., Toner, G., Gurney, H., McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
  • King, M., Hall, J., Caleo, S., Gurney, H., Harnett, P. (2000). Home or Hospital? An evaluation of the costs, preferences and outcomes of domiciliary chemotherapy. International Journal of Health Services, 30(3), 557-579.

To update your profile click here. For support on your academic profile contact .